This inspired the researchers to use data from Swedish nationwide registries to investigate how the use of individual GLP-1 agonists including exenatide, liraglutide, dulaglutide (Trulicity, Eli Lilly & Co.) and semaglutide (Ozempic/Wegovy, Novo Nordisk) would influence the risk for hospitalization due to AUD compared with periods of nonuse, with hospitalization due to substance use disorder (SUD), somatic reasons or suicide attempt serving as secondary outcomes
There are no human dosing protocols, no long-term safety data, and no way to verify the purity or composition of what arrives in the mail when you order it from a website that exists in a regulatory vacuum
Nauck MA, Kemmeries G, Holst JJ, Meier JJ
Human clinical work cited in popular press is generally fosgonimeton work, not Dihexa work